Dr. Reddy's CEO Dodges GSK Equity Deal Rumors - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Emotions should not come in the way of promoters wanting to sell their businesses, said Dr. Reddy's Labs Vice Chairman G.V. Prasad, while eluding questions pointed at a widely speculated equity deal between his company and GlaxoSmithKline
You may also be interested in...
Speculations Spark-off: Is A Deal Cooking Between Pfizer And India's Dr. Reddy's Labs?
MUMBAI - Repeated denials of an imminent sell-off by India's Dr. Reddy's Labs failed to subdue a fresh round of speculations that linked Pfizer, a company said to be interested in buying out the domestic formulations business from the Hyderabad-headquartered company. Pfizer did not wish to comment and Dr. Reddy's strongly denied any plans to sell
Speculations Spark-off: Is A Deal Cooking Between Pfizer And India's Dr. Reddy's Labs?
MUMBAI - Repeated denials of an imminent sell-off by India's Dr. Reddy's Labs failed to subdue a fresh round of speculations that linked Pfizer, a company said to be interested in buying out the domestic formulations business from the Hyderabad-headquartered company. Pfizer did not wish to comment and Dr. Reddy's strongly denied any plans to sell
Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs
MUMBAI - With six biosimilar compounds in the works and two launched in the Indian market, India's second largest generic drug maker - Dr. Reddy's Labs - is negotiating with several multinational companies to broaden its presence in Western markets